| 000 | 01769 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517120258.0 | ||
| 264 | 0 | _c20171026 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a2159-8290 | ||
| 024 | 7 |
_a10.1158/2159-8290.CD-16-0686 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBahcall, Magda | |
| 245 | 0 | 0 |
_aAcquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. _h[electronic resource] |
| 260 |
_bCancer discovery _c12 2016 |
||
| 300 |
_a1334-1341 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdenocarcinoma of Lung |
| 650 | 0 | 4 |
_aAnilides _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aErbB Receptors _xgenetics |
| 650 | 0 | 4 |
_aErlotinib Hydrochloride _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-met _xgenetics |
| 650 | 0 | 4 |
_aPyridines _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSim, Taebo | |
| 700 | 1 | _aPaweletz, Cloud P | |
| 700 | 1 | _aPatel, Jyoti D | |
| 700 | 1 | _aAlden, Ryan S | |
| 700 | 1 | _aKuang, Yanan | |
| 700 | 1 | _aSacher, Adrian G | |
| 700 | 1 | _aKim, Nam Doo | |
| 700 | 1 | _aLydon, Christine A | |
| 700 | 1 | _aAwad, Mark M | |
| 700 | 1 | _aJaklitsch, Michael T | |
| 700 | 1 | _aSholl, Lynette M | |
| 700 | 1 | _aJänne, Pasi A | |
| 700 | 1 | _aOxnard, Geoffrey R | |
| 773 | 0 |
_tCancer discovery _gvol. 6 _gno. 12 _gp. 1334-1341 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/2159-8290.CD-16-0686 _zAvailable from publisher's website |
| 999 |
_c26476048 _d26476048 |
||